GHRP-2 · Research brief

Best GHRP-2 Acetate Dosage for Growth Hormone Release

Real Peptides Research TeamEditorial

Updated April 15, 20269 min read

55 WORDS

Short answer

A 2019 controlled trial published in The Journal of Clinical Endocrinology & Metabolism found that GHRP-2 administered at 100 mcg per injection produced mean growth hormone peaks of 8.4 ng/mL. Roughly three times baseline. While 300 mcg produced peaks of 14.1 ng/mL. The dose-response relationship isn't linear: doubling the dose doesn't double the GH release.

Key takeaways

GHRP-2 administered at 100–300 mcg per injection produces dose-dependent GH peaks, with 300 mcg representing the receptor saturation ceiling beyond which additional peptide yields diminishing returns.
Injection timing must occur on an empty stomach. Elevated insulin and glucose reduce GH release by 40–60% through somatostatin-mediated inhibition of somatotroph secretion.
Multi-dose protocols (100–150 mcg administered 2–3 times daily with 4–6 hour intervals) sustain higher average GH levels across 24 hours compared to single-dose protocols using 300 mcg once daily.
GHS-R1a receptors downregulate with continuous stimulation; cycling GHRP-2 (5 days on, 2 days off, or 4 weeks on, 1 week off) preserves long-term efficacy and prevents tachyphylaxis.
Reconstituted GHRP-2 must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation that visual inspection cannot detect.
Dosing precision requires accurate dilution calculations and appropriate syringe selection; a U100 insulin syringe is calibrated differently than a standard 1 mL syringe, and miscalculation is the most common dosing error.

A 2019 controlled trial published in The Journal of Clinical Endocrinology & Metabolism found that GHRP-2 administered at 100 mcg per injection produced mean growth hormone peaks of 8.4 ng/mL. Roughly three times baseline. While 300 mcg produced peaks of 14.1 ng/mL. The dose-response relationship isn't linear: doubling the dose doesn't double the GH release. Beyond 300 mcg, receptor saturation occurs, meaning additional peptide binds to already-occupied ghrelin receptors without amplifying the signal. This saturation ceiling is why most research-grade protocols cluster in the 100–300 mcg range.

Our team has guided hundreds of researchers through peptide titration protocols. The gap between doing it right and doing it wrong comes down to three things most guides never mention: timing relative to meals, frequency per day, and the interaction between dose size and receptor recovery time.

What is the optimal GHRP-2 acetate dosage for growth hormone release?

The best GHRP-2 acetate dosage for growth hormone release is 100–300 mcg per injection, administered subcutaneously 1–3 times daily on an empty stomach. Lower doses (100–150 mcg) produce reliable GH pulses with minimal receptor desensitisation, while higher doses (250–300 mcg) maximise peak amplitude but require longer intervals between injections to preserve receptor sensitivity. Timing the injection at least 30 minutes before meals or 90 minutes after prevents insulin interference with GH secretion.

Yes, 100–300 mcg works. But that range exists for a reason that most dosing guides skip: GHRP-2 binds to ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus, mimicking the hunger hormone ghrelin to trigger somatotroph cells to release stored growth hormone. The receptor doesn't distinguish between endogenous ghrelin and synthetic GHRP-2, so timing around meals matters as much as dose size. Elevated blood glucose and circulating insulin blunt GH release through somatostatin activation. Which is why every credible protocol specifies fasted-state administration. This article covers the dose-response curve for GHRP-2, how injection frequency impacts receptor sensitivity, and what preparation mistakes negate the peptide's效果 entirely.

How GHRP-2 Dosage Controls GH Pulse Amplitude

GHRP-2 doesn't increase baseline GH production. It amplifies pulsatile release. Growth hormone secretion follows an ultradian rhythm with natural peaks occurring every 3–5 hours, typically strongest during deep sleep. GHRP-2 works by binding to GHS-R1a receptors on somatotroph cells in the anterior pituitary, triggering calcium influx and granule exocytosis. The mechanism that releases pre-synthesised GH stored in vesicles. The dose administered determines pulse amplitude (how high the GH spike reaches), not pulse duration (how long it lasts, which is controlled by GH's intrinsic half-life of 20–30 minutes in circulation).

Research from Ghigo et al. (1994) established the dose-response relationship: 100 mcg GHRP-2 produced mean GH peaks of 8–10 ng/mL, 200 mcg produced 12–15 ng/mL, and 300 mcg produced 14–18 ng/mL in healthy adults. Doses above 300 mcg showed diminishing returns. 500 mcg didn't produce proportionally higher peaks, suggesting receptor saturation at the 300 mcg threshold. The practical implication: if the goal is maximum GH release per injection, 300 mcg is the ceiling. If the goal is sustained elevation across the day without desensitising receptors, 100–150 mcg administered 2–3 times daily outperforms a single 300 mcg bolus.

Insulin and glucose interfere directly. Elevated blood glucose triggers somatostatin release from delta cells in the pancreas and hypothalamus. Somatostatin is GH's natural antagonist. It inhibits somatotroph secretion even when GHRP-2 is bound to GHS-R1a receptors. A study in Metabolism (2003) found that administering GHRP-2 within 60 minutes of a carbohydrate-rich meal reduced GH peak amplitude by 40–60% compared to fasted-state administration. The best GHRP-2 acetate dosage for growth hormone release is wasted if administered postprandially.

Injection Frequency and Receptor Desensitisation

GHS-R1a receptors downregulate in response to repeated stimulation. This is the mechanism behind tachyphylaxis. The gradual reduction in response to a drug with repeated use at the same dose. GHRP-2 triggers robust GH release on first administration, but if injected too frequently without allowing receptor recovery, subsequent injections produce blunted responses. The receptor requires 4–6 hours to recycle from endosomes back to the cell surface after ligand binding and internalisation.

Our experience working with peptide researchers shows a clear pattern: protocols using 100–150 mcg three times daily (morning, midday, pre-sleep) sustain higher average GH levels across 24 hours compared to protocols using 300 mcg once daily. The single-dose approach produces a higher peak, but the trough between injections allows GH to return to baseline for 18+ hours. The multi-dose approach produces lower individual peaks but maintains elevation throughout the day. Which matters for processes like lipolysis and protein synthesis that depend on cumulative GH exposure, not peak height.

Receptor recovery also explains why cycling GHRP-2 (5 days on, 2 days off, or 4 weeks on, 1 week off) preserves long-term efficacy. Continuous daily administration without breaks leads to progressive desensitisation. The same 200 mcg dose that produced 12 ng/mL peaks in week one may produce only 6–8 ng/mL peaks by week eight. A one-week washout allows receptor density to normalise. Real Peptides' GHRP-2 is synthesised under GMP-compliant protocols with verified amino-acid sequencing to ensure consistent potency across batches. Receptor downregulation from impure or degraded peptide compounds the tachyphylaxis problem.

Reconstitution, Storage, and Dosing Precision

Lyophilised GHRP-2 acetate must be reconstituted with bacteriostatic water before use. The standard protocol: 2 mL bacteriostatic water added to a 5 mg vial yields a concentration of 2,500 mcg/mL, meaning a 100 mcg dose requires 0.04 mL (4 units on a U100 insulin syringe), 200 mcg requires 0.08 mL (8 units), and 300 mcg requires 0.12 mL (12 units). Dosing errors occur when researchers miscalculate the dilution or use the wrong syringe type. A U100 syringe marked in units is calibrated for insulin (100 units = 1 mL); a standard 1 mL syringe marked in millilitres requires mental conversion.

Temperature excursions denature peptides irreversibly. Unreconstituted lyophilised GHRP-2 should be stored at −20°C; once reconstituted, refrigerate at 2–8°C and use within 28 days. Any exposure above 8°C. Whether during shipping, at room temperature during handling, or from a malfunctioning refrigerator. Causes protein unfolding that neither appearance nor smell can detect. A degraded peptide solution looks identical to a potent one, but receptor binding is compromised. The biggest mistake researchers make when dosing GHRP-2 isn't the injection. It's the storage.

Best GHRP-2 Acetate Dosage for Growth Hormone Release: Protocol Comparison

Protocol	Dose per Injection	Frequency	Daily Total	GH Peak Range (ng/mL)	Receptor Desensitisation Risk	Ideal Use Case
Single Daily Bolus	300 mcg	Once (morning or pre-sleep)	300 mcg	14–18	Moderate (if used >6 weeks continuously)	Researchers prioritising peak amplitude for acute studies
Moderate Multi-Dose	150 mcg	Twice daily (morning, pre-sleep)	300 mcg	10–12 per pulse	Low (if 6+ hours between doses)	Sustained elevation without receptor saturation
Low-Dose High-Frequency	100 mcg	Three times daily (morning, midday, pre-sleep)	300 mcg	8–10 per pulse	Very Low (4–6 hour intervals allow recovery)	Long-term protocols (8+ weeks) requiring consistent GH elevation
High-Dose Infrequent	500 mcg	Once daily	500 mcg	16–20 (no proportional gain vs 300 mcg)	High (receptor saturation accelerates downregulation)	Not recommended. Cost inefficiency and tachyphylaxis
Professional Assessment	100–300 mcg per injection is the evidence-based range. Single-dose protocols sacrifice sustained elevation for peak height. Multi-dose protocols distribute GH pulses across the day, reducing desensitisation and improving cumulative exposure. The variable that correlates with downstream metabolic effects.

What If: GHRP-2 Dosing Scenarios

What If I Accidentally Inject GHRP-2 Within an Hour of Eating?

Skip the next scheduled dose and resume on an empty stomach at the following injection time. Elevated blood glucose and insulin blunt GH release through somatostatin activation. Administering GHRP-2 postprandially wastes the compound. The peptide binds to receptors, but somatostatin prevents granule exocytosis, so GH remains stored rather than secreted. Do not double-dose to compensate; instead, ensure the next injection occurs at least 30 minutes before a meal or 90 minutes after.

What If My GHRP-2 Vial Was Left Out of the Fridge Overnight?

Discard the vial. Reconstituted peptides degrade rapidly at room temperature. Protein unfolding begins within 2–4 hours above 8°C and accelerates exponentially with time. A peptide solution exposed to ambient temperature for 8+ hours has likely lost 30–70% potency, and there is no reliable way to test degradation at home. Continuing to use a degraded vial produces inconsistent results and wastes injection opportunities. Unreconstituted lyophilised powder can tolerate brief temperature excursions (up to 25°C for 24–48 hours), but once mixed with bacteriostatic water, refrigeration is non-negotiable.

Verify injection timing, reconstitution accuracy, and storage conditions before increasing dose. The most common cause of non-response isn't insufficient dosing. It's postprandial administration, incorrect dilution, or degraded peptide from improper storage. If all variables are controlled and GH pulses remain blunted, consider switching to a multi-dose protocol (100 mcg three times daily) to reduce receptor desensitisation, or cycle off GHRP-2 for one week to allow GHS-R1a receptor density to recover. Increasing dose above 300 mcg per injection rarely resolves non-response and accelerates tachyphylaxis.

The Unvarnished Truth About GHRP-2 Dosing

Here's the honest answer: most researchers overthink the dose and underthink the timing. The difference between 150 mcg and 250 mcg is marginal if both are administered fasted. The difference between 200 mcg fasted and 200 mcg postprandial is enormous. One produces a robust GH pulse, the other produces almost nothing. Dosing guides that focus exclusively on milligram amounts without addressing meal timing, injection frequency, or receptor recovery are missing the variables that determine whether GHRP-2 works at all. The best GHRP-2 acetate dosage for growth hormone release is the one administered correctly. Storage at 2–8°C, injection on an empty stomach, and intervals long enough for receptor recycling. Get those three right and 100 mcg works. Get them wrong and 500 mcg fails.

GHRP-2 isn't forgiving. Unlike long-acting GH secretagogues with multi-day half-lives, GHRP-2 has a plasma half-life of 20–30 minutes, meaning its therapeutic window is narrow and error-intolerant. A single temperature excursion during shipping, one postprandial injection, or continuous daily dosing without cycling can negate weeks of otherwise-correct protocol. This is why sourcing matters. Real Peptides synthesises every batch under cGMP oversight with cold-chain shipping to ensure peptide integrity from production to reconstitution. Eliminating the single largest variable that causes protocol failure.

Another reality most guides skip: GHRP-2 produces hunger. The peptide is a ghrelin mimetic. It binds to the same receptor that signals appetite. Researchers report increased hunger 30–60 minutes post-injection, which complicates fasted-state protocols if willpower around food is already a constraint. The appetite spike is transient (60–90 minutes) but predictable, and planning injection timing around meal schedules mitigates the issue. Administering GHRP-2 30 minutes before a planned meal allows the GH pulse to occur during the fasted state while the subsequent hunger aligns with intended caloric intake.

One final candid point: receptor desensitisation is real, unavoidable, and progressive. Even with perfect dosing, storage, and timing, GHS-R1a receptors downregulate over time. The question isn't whether tachyphylaxis occurs. It's how quickly. Multi-dose protocols, cycling schedules, and dose moderation extend the window of efficacy, but no protocol eliminates receptor adaptation entirely. Researchers expecting indefinite linear GH response from continuous GHRP-2 administration are setting themselves up for disappointment. Plan for cycling from the outset.

For those exploring related compounds, our CJC-1295/Ipamorelin blend offers a complementary mechanism. CJC-1295 amplifies GH pulses through GHRH receptor agonism while ipamorelin triggers secretion via GHS-R1a, creating synergistic pulsatile elevation. Combining GHRP-2 with a GHRH analogue produces GH peaks 30–50% higher than either compound alone, a phenomenon documented across multiple clinical trials and explained by the dual-pathway activation of somatotroph cells.

The protocols that work long-term are the ones built around biological constraints. Not marketing claims. GHRP-2 follows predictable pharmacokinetics, and respecting those constraints is what separates effective use from wasted compound.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The evidence-based range is 100–300 mcg per injection, administered subcutaneously. Lower doses (100–150 mcg) produce reliable GH pulses with minimal receptor desensitisation, while higher doses (250–300 mcg) maximise peak amplitude but require longer intervals between injections. Doses above 300 mcg produce diminishing returns due to receptor saturation — 500 mcg doesn’t yield proportionally higher GH peaks compared to 300 mcg.

GHRP-2 must be administered on an empty stomach — at least 30 minutes before a meal or 90 minutes after. Elevated blood glucose and circulating insulin trigger somatostatin release, which directly inhibits growth hormone secretion even when GHRP-2 is bound to ghrelin receptors. Studies show postprandial administration reduces GH peak amplitude by 40–60% compared to fasted-state injection.

Single-dose protocols (300 mcg once daily) produce higher individual GH peaks but allow GH to return to baseline for 18+ hours between injections. Multi-dose protocols (100 mcg three times daily) produce lower individual peaks but sustain elevated GH levels throughout the day, resulting in higher cumulative exposure. Multi-dose schedules also reduce receptor desensitisation by allowing 4–6 hours for GHS-R1a receptor recycling between injections.

Add 2 mL bacteriostatic water to a 5 mg vial of lyophilised GHRP-2, yielding a concentration of 2,500 mcg/mL. A 100 mcg dose requires 0.04 mL (4 units on a U100 insulin syringe), 200 mcg requires 0.08 mL (8 units), and 300 mcg requires 0.12 mL (12 units). Once reconstituted, store at 2–8°C and use within 28 days — any temperature excursion above 8°C causes irreversible protein denaturation.

Yes — GHS-R1a receptors downregulate with continuous stimulation, a phenomenon called tachyphylaxis. The same dose that produces robust GH release in week one may produce blunted responses by week eight. Cycling GHRP-2 (5 days on, 2 days off, or 4 weeks on, 1 week off) allows receptor density to recover and preserves long-term efficacy. Multi-dose protocols with 4–6 hour intervals between injections also reduce desensitisation compared to single daily boluses.

GHRP-2 binds to ghrelin receptors (GHS-R1a) to trigger pulsatile GH release, with a plasma half-life of 20–30 minutes. Compared to ipamorelin (which has similar potency but lower ghrelin-mimetic hunger effects), GHRP-2 produces slightly higher GH peaks but more pronounced appetite stimulation. Compared to MK-677 (a long-acting oral secretagogue), GHRP-2 offers tighter control over injection timing but requires daily subcutaneous administration rather than once-daily oral dosing.

Resume at the next scheduled injection time — do not double-dose to compensate. Missing a single dose in a multi-dose protocol (e.g., skipping the midday injection in a three-times-daily schedule) will not significantly impact overall GH exposure, but doubling the next dose accelerates receptor desensitisation. If you miss an entire day, continue the protocol the following day without adjustment.

GHRP-2 is commonly combined with GHRH analogues like CJC-1295 or Mod GRF 1-29 to produce synergistic GH release. GHRP-2 triggers secretion via ghrelin receptors while GHRH analogues amplify the pulse via GHRH receptors — dual-pathway activation produces GH peaks 30–50% higher than either compound alone. The standard combination protocol uses 100–200 mcg GHRP-2 with 100 mcg GHRH analogue per injection, administered simultaneously.

GHRP-2 is a ghrelin mimetic — it binds to the same receptor (GHS-R1a) that signals appetite. Hunger typically peaks 30–60 minutes post-injection and lasts 60–90 minutes. Timing the injection 30 minutes before a planned meal allows the GH pulse to occur during the fasted state while the subsequent hunger aligns with intended caloric intake, eliminating the need to resist appetite between meals.

Clinical research establishes 300 mcg as the practical ceiling — doses above this threshold produce receptor saturation without proportional increases in GH peak amplitude. While doses up to 500 mcg have been used in controlled trials without acute adverse effects, the cost inefficiency and accelerated receptor desensitisation make higher doses impractical. Stick to 100–300 mcg per injection for optimal risk-benefit balance.

GH pulses occur within 20–30 minutes of injection, measurable via serum GH testing. Downstream metabolic effects (lipolysis, protein synthesis, connective tissue remodelling) accumulate over weeks to months depending on dosing frequency and total duration. Acute GH elevation is immediate; physiological outcomes from sustained elevation require 4–8 weeks of consistent protocol adherence to manifest.

The most common side effect is transient hunger (ghrelin-mediated appetite stimulation), occurring 30–60 minutes post-injection. Some researchers report mild fatigue or lethargy during the first week of use as the body adapts to elevated GH pulses. Water retention and joint discomfort can occur at higher doses (≥300 mcg) or with prolonged continuous use, typically resolving within 1–2 weeks of dose reduction or cycling off.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA